https://www.selleckchem.com/pr....oducts/pnd-1186-vs-4
Twenty-five (62.5%) patients experienced downstaging after neoadjuvant chemotherapy. Patients with 20% pretreatment Ki-67 and decrease of Ki-67 between pre- and post-neoadjuvant chemotherapy showed a trend for better response. In multivariate analysis, advanced pathological stage showed a significant negative effect on relapse-free survival. Conclusions Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predic
Curtir
Comentario
Compartilhar
